Colon | Esophagus | Liver | Pancreas, Phase II
An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors
Volunteers
Health Professionals
What is the purpose of this trial?
The purpose of this study is to determine the safety and efficacy of belzutifan in combination with pembrolizumab and lenvatinib in multiple solid tumors including hepatocellular carcinoma (HCC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC), endometrial cancer (EC),and esophageal squamous cell carcinoma (ESCC). There is no formal hypothesis testing in this study.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Agatha Hecht
- Andrea Brennan
- Armand Russo, MD
- Brooke Chaves
- David Witt, MD
- Harold Tara Jr, MD
- Jade Vanacore
- James Vredenburgh, MD
- Jane Kanowitz, MD
- Jeremy Kortmansky, MD
- Jill Lacy, MD
- Jose Morales-Marin
- Kristen Hoxie
- Laura Van Metre Baum, MD, MPH
- Madeline Santiago
- Michael Cohenuram, MD
- Neal Fischbach, MD
- Pamela L. Kunz, MD
- Pawan Karanam, MD
- Samantha Couillard
- Sara Anastasio, RN
- Stacey Stein, MD
- Teresa White
- Vanna Dest
- Vidya Kesavan
- Virginia Syombathy
- Xuanthao Thi Nguyen
- Zia Rahman, MD
- Last Updated11/14/2023
- Study HIC#2000031535